BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19659570)

  • 1. NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.
    Buac K; Xu M; Cronin J; Weeraratna AT; Hewitt SM; Pavan WJ
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):773-84. PubMed ID: 19659570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
    Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
    Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
    Capparelli C; Rosenbaum S; Berger AC; Aplin AE
    J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
    Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
    Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
    Gordon-Thomson C; Jones J; Mason RS; Moore GP
    Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
    Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
    Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
    Fock V; Plessl K; Draxler P; Otti GR; Fiala C; Knöfler M; Pollheimer J
    J Cell Sci; 2015 Dec; 128(23):4306-16. PubMed ID: 26490994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
    Capparelli C; Rosenbaum S; Berman-Booty LD; Salhi A; Gaborit N; Zhan T; Chervoneva I; Roszik J; Woodman SE; Davies MA; Setiady YY; Osman I; Yarden Y; Aplin AE
    Cancer Res; 2015 Sep; 75(17):3554-67. PubMed ID: 26206558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.
    Ieguchi K; Fujita M; Ma Z; Davari P; Taniguchi Y; Sekiguchi K; Wang B; Takada YK; Takada Y
    J Biol Chem; 2010 Oct; 285(41):31388-98. PubMed ID: 20682778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling.
    Shi DM; Li LX; Bian XY; Shi XJ; Lu LL; Zhou HX; Pan TJ; Zhou J; Fan J; Wu WZ
    J Exp Clin Cancer Res; 2018 Nov; 37(1):294. PubMed ID: 30486894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.
    Alver TN; Lavelle TJ; Longva AS; Øy GF; Hovig E; Bøe SL
    Oncotarget; 2016 Aug; 7(34):55128-55140. PubMed ID: 27391157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation.
    Bellei B; Pitisci A; Catricalà C; Larue L; Picardo M
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):309-25. PubMed ID: 21040502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
    Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA
    J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
    Hansen MR; Roehm PC; Chatterjee P; Green SH
    Glia; 2006 Apr; 53(6):593-600. PubMed ID: 16432850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
    Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
    Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
    Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
    PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.